Remittix is set to add 41 new fiat currencies to its PayFi ecosystem, enhancing crypto-to-bank and bank-to-crypto transactions globally ahead of its November 24 RTX launch. This expansion aims to support more international markets and users, including workers and merchants, by simplifying access between digital assets and traditional banking. Concurrently, XRP Ledger's November update and Ethereum's faster settlement plans have revived bullish price targets of $20 for XRP and $12,000 for Ethereum, reinforcing positive sentiment in the digital payments space. Remittix's growth and these blockchain developments position it as a notable player in bridging crypto with everyday finance.
Remittix's expansion of fiat currencies and XRP Ledger's update provide context for the digital payments sector. For readers following this space, here is Pluang's market snapshot as of Oct 22, 2026 23:01 WIB: Of 150 priced US stocks, 71 rose and 79 fell. Notable movers include PG at USD 166.57 with a 6.10% gain and UMC at USD 18.61 with a 6.10% loss.
First Pacific Bancorp announced solid third quarter 2026 results, with total assets reaching $532 million, up $42 million from year-end 2025. Deposits increased to $449 million, and loans grew to $362 million, reflecting steady balance sheet expansio...
ICEYE and Nokia have signed a Letter of Intent with Ukraine's Ministry of Defence to collaborate on building sovereign satellite communication capabilities. This partnership aims to enhance Ukraine's defense by providing secure, high-performance sate...
Dayton T. Brown, Inc. inaugurated its new 104,000-square-foot Test & Qualification Center in Huntsville, Alabama, enhancing its capacity to support aerospace, defense, and propulsion programs. The facility's strategic location near Huntsville's aeros...
A new study by The Grossman Group reveals that while 60% of chief communications officers (CCOs) have influence at the leadership level, their communications functions lack the necessary systems, skills, and AI capabilities to fully meet their mandat...
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
